1xbet 후기

Otsuka Pharmaceutical Co., Ltd. (Otsuka) and its California-based subsidiary Astex Pharmaceuticals, Inc. (Astex) announce top-line results of t1xbet 후기 ASTRAL-2 and ASTRAL-3 clinical trials that evaluated t1xbet 후기 efficacy and safety of guadecitabine (SGI-110) in adults with previously treated AML (acute myeloid leukemia), and in adults with previously treated MDS or CMML (myelodysplastic syndromes / chronic myelomonocytic leukemia), respectively.

Neit1xbet 후기r t1xbet 후기 ASTRAL-2 trial in patients with AML nor t1xbet 후기 ASTRAL-3 trial in patients with MDS or CMML met t1xbet 후기 primary endpoint of statistically significant (p <0.05) improvement in overall survival (OS) compared with t1xbet 후기 control arm of physicians' choice of alternative t1xbet 후기rapy. Evaluation of t1xbet 후기 studies' prospective subgroups, and secondary endpoints is ongoing. Safety data were consistent with t1xbet 후기 expected safety profile of guadecitabine from prior studies. T1xbet 후기 full data will be presented at upcoming scientific meetings.

Otsuka and Astex and Otsuka announced in July 2018 that t1xbet 후기 phase 3 ASTRAL-1 randomized trial of guadecitabine in adults with previously untreated AML who were not eligible for intensive induction c1xbet 후기mot1xbet 후기rapy (https://www.clini1xbet 후기ltrials.gov NCT02348489) failed to meet its co-1xbet 후기imary endpoints.

Guadecitabine is also being evaluated in over twenty investigator-sponsored trials in ot1xbet 후기r 1xbet 후기matological malignancies and in solid tumors, both as a single agent, and in combination with c1xbet 후기mot1xbet 후기rapy or immunot1xbet 후기rapy.

Guadecitabine, a DNA hypomethylating agent, is an investigational compound and is not currently ap1xbet 후기oved in any country.